Literature DB >> 28352399

Thrombosis of A Prosthetic Mitral Valve After Withdrawal of Phenprocoumon Therapy.

Andreas Wilke1, Christian M Wende2, Michael Horst3, Dietmar Steverding4.   

Abstract

Patients with prosthetic heart valves require lifelong oral anticoagulant therapy based on vitamin K antagonists. These patients may need interruption of their anticoagulant therapy if they have to undergo surgery. The clinical challenge is to identify patients who can safely undergo surgery while continuing their vitamin K antagonist treatment and those who have to take short-acting heparin as part of a bridging therapy. Here we present a case of a patient with a prosthetic mitral valve whose oral anticoagulant therapy was unnecessarily discontinued by the GP prior to an upcoming cataract surgery. As a result, the patient developed thrombosis of the prosthetic mitral valve which needed to be surgically replaced.

Entities:  

Keywords:  Bridging therapy; Oral anticoagulant therapy; Prosthetic heart valve thrombosis

Year:  2011        PMID: 28352399      PMCID: PMC5358259          DOI: 10.4021/cr124w

Source DB:  PubMed          Journal:  Cardiol Res        ISSN: 1923-2829


  6 in total

Review 1.  Oral anticoagulant therapy. Fundamentals, clinical practice and recommendations.

Authors:  R Lemos Silva; J Carvalho de Sousa; C Calisto; J M Braz Nogueira; Luciano Ravara
Journal:  Rev Port Cardiol       Date:  2007 Jul-Aug       Impact factor: 1.374

Review 2.  Periprocedural reversal and bridging of anticoagulant treatment.

Authors:  M Levi; E Eerenberg; P W Kamphuisen
Journal:  Neth J Med       Date:  2011-06       Impact factor: 1.422

Review 3.  Antithrombotic therapies in patients with prosthetic heart valves: guidelines translated for the clinician.

Authors:  Tiago L L Leiria; Renato D Lopes; Judson B Williams; Jason N Katz; Renato A K Kalil; John H Alexander
Journal:  J Thromb Thrombolysis       Date:  2011-05       Impact factor: 2.300

Review 4.  Update in bridging anticoagulation.

Authors:  Scott Kaatz; David Paje
Journal:  J Thromb Thrombolysis       Date:  2011-04       Impact factor: 2.300

5.  Pharmacokinetics of phenprocoumon.

Authors:  K O Haustein; G Hüller
Journal:  Int J Clin Pharmacol Ther       Date:  1994-04       Impact factor: 1.366

Review 6.  Periprocedural thromboprophylaxis in patients receiving chronic anticoagulation therapy.

Authors:  Syed M Jafri
Journal:  Am Heart J       Date:  2004-01       Impact factor: 4.749

  6 in total
  1 in total

1.  Vitamin K Antagonist (Phenprocoumon) and Subarachnoid Hemorrhage: A Single-Center, Matched-Pair Analysis.

Authors:  Markus Bruder; Sepide Kashefiolasl; Nina Brawanski; Fee Keil; Sae-Yeon Won; Volker Seifert; Juergen Konczalla
Journal:  Neurocrit Care       Date:  2020-08       Impact factor: 3.210

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.